The U.S. on Thursday launched missile strikes against Syria in retaliation for chemical attacks on the Middle Eastern country’s own citizens. There are sure to be geopolitical ramifications. For investors, here’s what’s happening to various asset classes as well as my predictions. The predictions are derived from the adaptive ZYX
Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the
This post was just published on ZYX Short Sell Change Alert. SUN is running up because it sold some assets to the Japanese company that owns 7-Eleven for a price higher than its market cap. Momo crowd is excited and aggressively buying the stock. The momo crowd is missing in its analysis the
The high-flying U.S. stock market will crash if President Trump keeps his promise of trade protectionism against China. Please note that I used the word “will” instead of “might.” That’s quite a conviction on my part, given my second law of investing states: “Nobody knows with certainty what is going
This post was published on ZYX Short Sell Change Alert. 3-D printer maker VJET is short from $69.43. As of this writing it is trading at $2.70. The company reported reasonably good earnings and a large bank upgraded it to a buy. However in spite of good earnings and the upgrade, the
Samsung last week introduced its new flagship smartphone, the Galaxy S8, after being forced to withdraw the previous model from the market because battery defects caused them to occasionally overheat and combust or explode. The Galaxy S8 is getting glowing reviews. And investors are now asking me whether the Samsung SSNLF smartphone
This post was just published on ZYX Short Sell Change Alert. ACOR is short from $48.73. The stock was halted at $20.33, down $6.44. The stock was being crushed before the halt as patents on Ampyra are invalidated. ACOR came to fame on Ampyra, a drug that marginally helps MS patients’ walking. We
Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the
This post was just published on ZYX Buy Change Alert. AAAP, Steve Jobs cancer drug company, appears to be breaking out. Please see prior post on AAAP. This information is useful only for short-term aggressive traders. Long-term conservative investors may ignore this post. You are receiving less than 2% of the content
Many investors have seen their “stops” — orders to sell securities to protect from losses — triggered only to see the stock market reverse course and post gains. Other investors have ended up selling securities on technical signals, and then the market does the opposite. I have received many questions